Antisoma Buys Oncology Firm Xanthus
This article was originally published in The Pink Sheet Daily
Executive Summary
Through deal, Antisoma acquires Xanafide in Phase III for secondary AML and oral fludarabine, awaiting FDA approval.
You may also be interested in...
Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.
Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.
Oral Fludarabine Gives Antisoma Breathing Room
Antisoma’s deal with Sanofi-Aventis provides two years of cash, allowing the biotech to focus on its pipeline.